An analysis report released by the National Development and Reform Commission of the pharmaceutical industry this year shows that since the beginning of this year, the pharmaceutical industry has realized a total output value of 113.4 billion yuan, and realized a total profit of 7.89 billion yuan, a year-on-year increase of only 6.3%. The growth rate has dropped sharply and dropped to a historical low. point. However, medical equipment and equipment, Chinese Herbal Medicine Pieces, and sanitary materials and medical supplies achieved profits of 7.2, 1.3, and 300 million yuan, respectively, an increase of 80.7%, 33%, and 30% year-on-year. The growth rate of chemical drug preparations, proprietary Chinese medicines, and biochemical products is lower than the industry average.
With the improvement of the people's living standards, the pharmaceutical industry has also given birth to great development prospects, and the share of the pharmaceutical market will grow. However, the continuous increase in the cost of pharmaceutical production will become a bottleneck in the development of medicine. The upstream production factors such as water, electricity, and coal continue to be at higher prices, making the pharmaceutical production costs relatively high. The rise of raw materials will be the challenge that the pharmaceutical industry must face in the future. Therefore, how to develop finished drugs with independent intellectual property rights, how to expand the export of drugs is the main direction for the future development of pharmaceutical companies. At present, China's western medicine mainly exports APIs, and its finished products are mainly exported domestically. Exports are very small. Although many Chinese medicine companies are developing towards industrialization, their export prospects are not optimistic. At present, the main exports of Chinese medicine are still Mainly in Southeast Asia, Europe and the United States and other developed countries still can not agree with traditional Chinese medicine theory, so how to develop finished products with independent intellectual property rights, how to expand the amount of exports of pharmaceuticals will become the top priority of the development of the industry.
In the future, the differentiation within the pharmaceutical industry will expand even further. Traditional Chinese medicine decoction pieces produced from the industrialization of traditional Chinese medicine, and sanitary materials and medicines with a high market share will both increase substantially, while some lower-tech raw materials and chemical drugs will suffer. The impact of drug price cuts will reduce the space for future development. The implementation of the generic drug name system will have a huge impact on the company's business decisions and market operations in the R&D, production, and marketing sectors. A group of companies with low capacity utilization and poor quality control will be forced to stop production. Some brands Powerful large companies will use integration to achieve scale and brand effect and win in the competition. Therefore, pharmaceutical companies with brand effects will have more development prospects, and the market is also more appreciative of this type of pharmaceutical industry, such as the old traditional Chinese medicine companies such as Dong-E Ejiao and G Tong Ren Tang, as well as sanitary materials and medicines with higher market share. The development prospects of the company are also very impressive. For example, G Renfu, which mainly produces anesthetic drugs, reported a substantial increase in performance.
Therefore, the continued differentiation of the pharmaceutical industry in the market will not be avoided. Among them, high-quality companies will also have many performances. For example, G Tai Chi, the company is one of the top ten companies in the pharmaceutical industry. The company's emergency syrup and Qumei weight loss products have a relatively large market share. In addition, after the company sells the shares of Tongjunge, it will receive the total net asset value of Tongjunge plus 40 million yuan in cash. Therefore, the outlook for the development of the company will be considerable. Although the increase in production costs will have a certain impact on the company, the company itself is confident in the product. Some of the company's traditional Chinese medicines such as Huoxiangzhengqi Soft Capsules will have a broader market. The company's stock price in the secondary market is relatively low, and its 19x P/E ratio is obviously lower than the market average price-earnings ratio. The market outlook can pay due attention.
With the improvement of the people's living standards, the pharmaceutical industry has also given birth to great development prospects, and the share of the pharmaceutical market will grow. However, the continuous increase in the cost of pharmaceutical production will become a bottleneck in the development of medicine. The upstream production factors such as water, electricity, and coal continue to be at higher prices, making the pharmaceutical production costs relatively high. The rise of raw materials will be the challenge that the pharmaceutical industry must face in the future. Therefore, how to develop finished drugs with independent intellectual property rights, how to expand the export of drugs is the main direction for the future development of pharmaceutical companies. At present, China's western medicine mainly exports APIs, and its finished products are mainly exported domestically. Exports are very small. Although many Chinese medicine companies are developing towards industrialization, their export prospects are not optimistic. At present, the main exports of Chinese medicine are still Mainly in Southeast Asia, Europe and the United States and other developed countries still can not agree with traditional Chinese medicine theory, so how to develop finished products with independent intellectual property rights, how to expand the amount of exports of pharmaceuticals will become the top priority of the development of the industry.
In the future, the differentiation within the pharmaceutical industry will expand even further. Traditional Chinese medicine decoction pieces produced from the industrialization of traditional Chinese medicine, and sanitary materials and medicines with a high market share will both increase substantially, while some lower-tech raw materials and chemical drugs will suffer. The impact of drug price cuts will reduce the space for future development. The implementation of the generic drug name system will have a huge impact on the company's business decisions and market operations in the R&D, production, and marketing sectors. A group of companies with low capacity utilization and poor quality control will be forced to stop production. Some brands Powerful large companies will use integration to achieve scale and brand effect and win in the competition. Therefore, pharmaceutical companies with brand effects will have more development prospects, and the market is also more appreciative of this type of pharmaceutical industry, such as the old traditional Chinese medicine companies such as Dong-E Ejiao and G Tong Ren Tang, as well as sanitary materials and medicines with higher market share. The development prospects of the company are also very impressive. For example, G Renfu, which mainly produces anesthetic drugs, reported a substantial increase in performance.
Therefore, the continued differentiation of the pharmaceutical industry in the market will not be avoided. Among them, high-quality companies will also have many performances. For example, G Tai Chi, the company is one of the top ten companies in the pharmaceutical industry. The company's emergency syrup and Qumei weight loss products have a relatively large market share. In addition, after the company sells the shares of Tongjunge, it will receive the total net asset value of Tongjunge plus 40 million yuan in cash. Therefore, the outlook for the development of the company will be considerable. Although the increase in production costs will have a certain impact on the company, the company itself is confident in the product. Some of the company's traditional Chinese medicines such as Huoxiangzhengqi Soft Capsules will have a broader market. The company's stock price in the secondary market is relatively low, and its 19x P/E ratio is obviously lower than the market average price-earnings ratio. The market outlook can pay due attention.
Disabled Electric Scooter,Fastest Electric Scooter,Eec Electric Scooters,Powerful Electric Scooter
Wuxi Jiangyin Xufeng Electric Bicycle Co., Ltd. , https://www.xufengrelxrides.com